Jesper Wiklund joins Klaria from New York based Oberland Capital, a health care focused private investment firm with over $1.2 billion in capital commitments where he served as Managing Director, Europe. Prior to that, he was CEO of InDex Pharmaceuticals Holding AB, a drug development company listed on NASDAQ First North and based in Stockholm, Sweden. Over the course of his 20+ year career in the life science industry, Jesper Wiklund has completed strategic transactions with an aggregate value exceeding $1 billion and he has raised four rounds of Venture Capital from top-tier European Investors. He was born in 1969, holds an MBA from Harvard Business School and a Bachelor of Science in Biology from St. Mary’s College of California. Jesper Wiklund owns 1 203 654 shares in Klaria Pharma.
Dependent in relation to the major shareholders.
Dependent in relation to the company and company management.
Chief Scientific Officer (Since 2019)
Scott Boyer is a co-founder of Klaria. As Chief Scientific Officer, Scott Boyer oversees research, clinical development and regulatory affairs. Prior to joining Klaria, he was Chief Scientist at AstraZeneca with global responsibility for molecular and investigational toxicology across Astra Zeneca and he was a member of the AZ senior management team. Prior to that, he was Senior Research Scientist at Pfizer. Scott Boyer has a Ph.D from the University of Colorado, Boulder in Molecular Toxicology. He completed a NIH Fogarty International Center Postdoctoral Fellowship at the Karolinska Institute. Scott Boyer owns 731 042 shares in Klaria Pharma.
Independent in relation to the major shareholders.
Dependent in relation to the company and company management.
Marc Willuhn works as our Head of CMC (Chemistry, Manufacturing and Control). Previously, he was VP R&D at Fresenius Kabi and Head of the Innovation & Development Centre in Uppsala, Sweden. Prior to that, he was Director of Process Development at Baxter Healthcare. Earlier in his career, Marc Willuhn worked in chemical development at Schering AG and Sigma-Aldrich. He obtained his PhD in organic chemistry at the Max Planck Institute for Coal Research in Germany and carried out post-doctoral research at the Faculté de Pharmacie in Paris, France. Marc Willuhn owns 25 000 shares in Klaria Pharma.
